RxDoctor Payments Data

Alicia Skarimbas, MD

Family Medicine · Englewood, NJNPI 1245239490

Payments from drug & device makers

$1,827in general payments, 2019–2025

Across 123 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$293
  • AbbVie$197
  • Novo Nordisk$162
  • Merck$149
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$117
  • Amgen$70
  • plus $839 from 24 others

What the payments were for

  • Food & beverage$1,827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,827 in reported general payments places this provider in the 75th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$246,454
Medicare patients
555
Services billed
2,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban436$136,121
OzempicSemaglutide27$42,221
JardianceEmpagliflozin76$32,202
MounjaroTirzepatide28$29,192
JanuviaSitagliptin Phosphate119$27,023
EntrestoSacubitril/Valsartan55$20,918
MyrbetriqMirabegron68$17,915
ZonisadeZonisamide15$16,827
Breo ElliptaFluticasone/Vilanterol31$15,058
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,506
XareltoRivaroxaban43$13,314
Mirtazapine451$10,308
ZenpepLipase/Protease/Amylase12$9,404
FarxigaDapagliflozin Propanediol37$8,166
GemtesaVibegron29$7,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$41$140,676450 claims
Novo NordiskOzempic$162$42,22127 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$66$36,86871 claims
Lilly USA, LLCMounjaro$64$29,19228 claims
MerckJanuvia$149$27,023119 claims
NovartisEntresto$63$20,91855 claims
Astellas Pharma US IncMyrbetriq$15$17,91568 claims
AstraZenecaFarxiga, Brilinta$28$15,00552 claims
Johnson & JohnsonXarelto$293$13,31443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →